Regulatory considerations for developing remote measurement technologies for Alzheimer’s disease research
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Regulatory considerations for developing remote measurement technologies for Alzheimer’s disease research ; volume:7 ; number:1 ; day:4 ; month:9 ; year:2024 ; pages:1-6 ; date:12.2024
npj digital medicine ; 7, Heft 1 (4.9.2024), 1-6, 12.2024
- Creator
-
Erdemli, Gül
Grammatikopoulou, Margarita
Wagner, Bertil
Vairavan, Srinivasan
Curcic, Jelena
Aarsland, Dag
Wittenberg, Gayle
Nikolopoulos, Spiros
Muurling, Marijn
Fröhlich, Holger
Boer, Casper de
Shanbhag, Niraj M.
Nies, Vera J. M.
Coello, Neva
Gove, Dianne
Diaz, Ana
Foy, Suzanne
Dartee, Wim
Brem, Anna-Katharine
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41746-024-01211-8
- URN
-
urn:nbn:de:101:1-2411202140100.903664591245
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Erdemli, Gül
- Grammatikopoulou, Margarita
- Wagner, Bertil
- Vairavan, Srinivasan
- Curcic, Jelena
- Aarsland, Dag
- Wittenberg, Gayle
- Nikolopoulos, Spiros
- Muurling, Marijn
- Fröhlich, Holger
- Boer, Casper de
- Shanbhag, Niraj M.
- Nies, Vera J. M.
- Coello, Neva
- Gove, Dianne
- Diaz, Ana
- Foy, Suzanne
- Dartee, Wim
- Brem, Anna-Katharine
- SpringerLink (Online service)
Other Objects (12)
Remote monitoring technologies in Alzheimer’s disease: design of the RADAR-AD study
Practical considerations for choosing a mouse model of Alzheimer’s disease
Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease
Surface analysis for Alzheimer’s
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
Intranasal Insulin for Alzheimer’s Disease
Photoaffinity Probes for Alzheimer’s Disease
Blood biomarkers for Alzheimer’s disease
Neuroimaging Biomarkers for Alzheimer’s Disease
Active immunotherapy options for Alzheimer’s disease
Urinary metabolic phenotyping for Alzheimer’s disease
Probing neural circuit mechanisms in Alzheimer’s disease using novel technologies
Remote monitoring technologies in Alzheimer’s disease: design of the RADAR-AD study
Practical considerations for choosing a mouse model of Alzheimer’s disease
Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease
Surface analysis for Alzheimer’s
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
Intranasal Insulin for Alzheimer’s Disease
Photoaffinity Probes for Alzheimer’s Disease
Blood biomarkers for Alzheimer’s disease
Neuroimaging Biomarkers for Alzheimer’s Disease
Active immunotherapy options for Alzheimer’s disease
Urinary metabolic phenotyping for Alzheimer’s disease
Probing neural circuit mechanisms in Alzheimer’s disease using novel technologies
Remote monitoring technologies in Alzheimer’s disease: design of the RADAR-AD study
Practical considerations for choosing a mouse model of Alzheimer’s disease
Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease
Surface analysis for Alzheimer’s
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
Intranasal Insulin for Alzheimer’s Disease
Photoaffinity Probes for Alzheimer’s Disease
Blood biomarkers for Alzheimer’s disease
Neuroimaging Biomarkers for Alzheimer’s Disease
Active immunotherapy options for Alzheimer’s disease
Urinary metabolic phenotyping for Alzheimer’s disease